

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO ALLIA.143A	APPLICATION NO. 08/779,767
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Habib Zaghouni	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE January 7, 1997	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PN	A	Liu et al. "Affinity for class II MHC determines the extent to which soluble peptides tolerize autoreactive T cells in naive and primed adult mice - implications for autoimmunity" <i>Int. Imm.</i> 7(8) 1255-1263 (1995)
PN	B	Karpus et al. "Inhibition of Relapsing Experimental Autoimmune Encephalomyelitis in SJL Mice by Feeding the Immunodominant PLP139-151 Peptide" <i>J. Neurosci. Res.</i> 45: 410-423 (1996)
PN	C	Karin et al. "Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myeline Basic Protein Epitope: T Cell Receptor Antagonism and Reduction of Interferon γ and Tumor Necrosis Factor α Production" <i>J. Exp. Med.</i> 180 2227 - 2237 (1994)

EXAMINER <i>Patrick J. Nolan</i>	DATE CONSIDERED <i>3/20/01</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT	